Navigation Links
Rapid development of drug-resistant 2009 H1N1 influenza reported in 2 cases
Date:3/26/2010

Two people with compromised immune systems who became ill with 2009 H1N1 influenza developed drug-resistant strains of virus after less than two weeks on therapy, report doctors from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Doctors who treat prolonged influenza infection should be aware that even a short course of antiviral treatment may lead to drug-resistant virus, say the authors, and clinicians should consider this possibility as they develop initial treatment strategies for their patients who have impaired immune function.

Both patients in the new report developed resistance to the key influenza drug oseltamivir (Tamiflu), and one also demonstrated clinical resistance to another antiviral agent, now in experimental testing, intravenous peramivir, note senior authors Matthew J. Memoli, M.D., and Jeffery K. Taubenberger, M.D., Ph.D. This is the first reported case of clinically significant peramivir-resistant 2009 H1N1 illness, say the scientists. The report is scheduled to appear in print on May 1 in Clinical Infectious Diseases and is now online.

The people in the current case report had immune limitations due to blood stem cell transplants that occurred several years previously. Both recovered from their influenza infections.

"While the emergence of drug-resistant influenza virus is not in itself surprising, these cases demonstrate that resistant strains can emerge after only a brief period of drug therapy," says NIAID Director Anthony S. Fauci, M.D. "We have a limited number of drugs available for treating influenza and these findings provide additional urgency to efforts to develop antivirals that attack influenza virus in novel ways."

The 2009 H1N1 influenza virus is susceptible to just one of the two available classes of anti-influenza drugs, the neuraminidase inhibitors. Besides oseltamivir, other neuraminidase inhibitors are zanamivir (Rel
'/>"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. FMI Introduces Rapid Development Program for Medical Silicone Components
2. New Hampshire Community Colleges Choose Rapid Insight for Data Reporting Needs
3. EE Technologies Adds High Speed Rapid Prototyping Line in Reno
4. Studies Show Doctors Rapidly Forget Critical, Life-Saving Skills such as CPR and Life Support
5. China rapidly catching up in research impact
6. Study shows new brain connections form rapidly during motor learning
7. Allscripts Announces Rapid Implementation, Meaningful Use Guarantee, and Financing Programs for Electronic Health Records
8. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
9. Rapid Flu Test Most Accurate for Young Kids
10. Artists, Product Designers, Printing Gurus, Game Developers, Manufacturing Engineers Will Converge at RAPID 2010/3D IMAGING Conference/Expo, May 18-20 in LA
11. Aspirus Eases Pain of Rapid Data Growth With an EMC Information Infrastructure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 2013 VHA Inc., the national ... automated, provider-led population health improvement, announced a new ... and successfully pursue population health management with ... to accelerate the transition to value-based models of ... improvement suite of services, the offering integrates VHA ...
(Date:5/20/2013)... Washington, D.C., May 20, 2013 CosmosID, a leading data ... as part of a collaboration results on analysis of ... speed, specificity, and accuracy. , The Food and Drug ... number of commercially available probiotics, four of which have ... The purpose of the tests was to compare the ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Headquartered in ... Levy Phillips & Konigsberg LLP (“LPK”) has ... White Plains, New York. LPK will better serve people ... Hudson Valley, including Westchester, Putnam, Rockland, Orange, and Dutchess ... affected by asbestos-related diseases throughout New York, New Jersey, ...
(Date:5/20/2013)... Finnish subjects and was led by Professor Samuli ... 28 genetic markers improved detection of individuals with ... risk ≥20%) over traditional risk factors. , Identification ... for CHD, because the current guidelines recommend statin ... that genetic markers could be useful in CHD ...
(Date:5/20/2013)... Dallas, TX (PRWEB) May 20, 2013 ... largest portfolio of employee benefit, payroll products and services ... announced that both are selected as finalists for the ... the Fastest-Growing Company of the Year category, and CompuPay ... Year. Each finalist will ultimately be a Gold, Silver ...
Breaking Medicine News(10 mins):Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4Health News:CosmosID unveils new tool for faster, specific and accurate testing of probiotics products 2Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 2Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 3Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 2Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 3
... , , ARLINGTON, ... Health and Human Services Office of Inspector General (OIG) ignored ... including complex rehab, to seniors and people with disabilities who ... the Medicare Program: Supplier Acquisition Costs and Services" and dated ...
... OKLAHOMA CITY, Sept. 3 Surgical Hospital of ... partnered with Surgical Care Affiliates (SCA), one of the country,s ... is a state of the art hospital providing surgical services ... pain management, podiatry and orthopedics. SCA and a number of ...
... done to protect young knees, ankles and shoulders, researcher says ... all high school sports injuries are bad enough to keep a ... the pack in severe injuries, a new U.S. study finds. , ... girls experienced a greater rate of severe injury than boys in ...
... worldunderstand and prepare for contagious outbreaks, the National Institutes ... adds new research expertise to increase its capacity to ... inform public health officials and policymakers. In ... and infected people around the world. In 2003, a ...
... delaying needed care ends up raising health-care costs, study ... -- Patients who don,t trust the health-care system are ... health and raising overall health care costs, a new ... majority of whom were black, about their attitudes toward ...
... , , , , ... entered into a definitive agreement under which Embla will acquire Covidien,s ... the Sandman(TM) brand name. Financial terms of the transaction were ... conditions. , , The combined entity will form ...
Cached Medicine News:Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 2Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 3Health News:Surgical Hospital of Oklahoma to Partner with Surgical Care Affiliates 2Health News:High School Sports Put Players at Risk for Severe Injuries 2Health News:New grants expand US infectious disease modeling effort 2Health News:New grants expand US infectious disease modeling effort 3Health News:Mistrust May Cause People to Put Off Treatment 2Health News:Embla(R) Systems Announces the Acquisition of the Sandman(R) Sleep Diagnostic Business from Covidien(R) - Creating the World's Largest Sleep Diagnostic Company 2
(Date:5/17/2013)... , May 17, 2013 Medical devices are ... a biological product. In light of their different mechanisms, ... are much more complicated than drug trails due to ... MD safety instead of evaluating both safety and efficacy ... FDA (which is the same as the SFDA) evaluate ...
(Date:5/17/2013)... DIEGO , May 17, 2013  Sorrento ... that its Fast-Track Advanced Technology Small Business Technology ... Institute of Allergy and Infectious Diseases (NIAID), a ... supporting the development of novel human antibody therapeutics ... aureus or Staph) infections, including methicillin-resistant ...
(Date:5/17/2013)... CHAPEL HILL, N.C. , May 17, 2013 ... on how organizations communicate internally. Faced with a ... adjust their strategies and tactics for communicating with ... the effectiveness of all the strategies, tactics and ... In a new study, Best ...
Breaking Medicine Technology:Statistical Challenges in Medical Device Trail Evaluation 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Internal Communication Strategies and Tactics that Resonate with Key Stakeholders and Drive Organizational Effectiveness 2
... a,biopharmaceutical company focused on the development of novel ... from its,Phase I safety and tolerability study of ... MRX-4 was nasally administered as a single ... first administration was given without a nasal,allergen challenge ...
... Applied,Biology, Inc. (FAB) announced today that it has ... IIB grant from the National,Science Foundation. The $500,000 ... cell-free protein synthesis technology towards commercialization., During ... Phase II,NSF projects, FAB successfully demonstrated that certain ...
Cached Medicine Technology:Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients 2Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: